Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Kim HS, Bang J, Naimi Z, Bosch-Castells V, Boaz M, Bouckenooghe A. Kim DS, et al. Hum Vaccin Immunother. 2014;10(9):2656-63. doi: 10.4161/hv.29743. Epub 2014 Nov 6. Hum Vaccin Immunother. 2014. PMID: 25483480 Free PMC article. Clinical Trial.
Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, Naimi Z, Bouckenooghe A, Bosch-Castells V, Houillon G. Kim DS, et al. Among authors: bosch castells v. Pediatr Infect Dis J. 2016 Feb;35(2):e60-4. doi: 10.1097/INF.0000000000000967. Pediatr Infect Dis J. 2016. PMID: 26535878 Clinical Trial.
Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil.
Medeiros R, Jusot V, Houillon G, Rasuli A, Martorelli L, Kataoka AP, Mechlia MB, Le Guern AS, Rodrigues L, Assef R, Maestri A, Lima R, Rotivel Y, Bosch-Castells V, Tordo N. Medeiros R, et al. Among authors: bosch castells v. PLoS Negl Trop Dis. 2016 Sep 21;10(9):e0004920. doi: 10.1371/journal.pntd.0004920. eCollection 2016 Sep. PLoS Negl Trop Dis. 2016. PMID: 27653947 Free PMC article.
A Safety and Immunogenicity Study of a Single Dose of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in Healthy Japanese Participants.
Fukushima S, Kikuchi H, Miyazu M, Hamada A, Ouchi K, Takagi H, Mihara H, Sasaki T, Oka H, Bosch-Castells V, Oster P. Fukushima S, et al. Among authors: bosch castells v. Jpn J Infect Dis. 2018 Nov 22;71(6):402-407. doi: 10.7883/yoken.JJID.2017.277. Epub 2018 Jun 29. Jpn J Infect Dis. 2018. PMID: 29962480 Free article. Clinical Trial.
Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
Quiambao BP, Ambas C, Diego S, Bosch Castells V, Korejwo J, Petit C, Houillon G. Quiambao BP, et al. Among authors: bosch castells v. Vaccine. 2019 Apr 10;37(16):2268-2277. doi: 10.1016/j.vaccine.2019.02.083. Epub 2019 Mar 16. Vaccine. 2019. PMID: 30890382 Free article. Clinical Trial.
Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
Quiambao BP, Ambas C, Diego S, Bosch Castells V, Korejwo J, Petit C, Rasuli A, Houillon G. Quiambao BP, et al. Among authors: bosch castells v. Vaccine. 2020 May 6;38(21):3740-3746. doi: 10.1016/j.vaccine.2020.03.043. Epub 2020 Apr 9. Vaccine. 2020. PMID: 32280042 Free article. Clinical Trial.
One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
Quiambao BP, Lim JG, Bosch Castells V, Augard C, Petit C, Bravo C, Delore V, Houillon G. Quiambao BP, et al. Among authors: bosch castells v. Vaccine. 2022 Aug 26;40(36):5347-5355. doi: 10.1016/j.vaccine.2022.07.037. Epub 2022 Aug 3. Vaccine. 2022. PMID: 35933278 Free article. Clinical Trial.
15 results